Show simple item record

dc.contributor.authorBrand, D
dc.contributor.authorParker, C
dc.date.accessioned2018-01-24T14:35:20Z
dc.date.issued2018-04
dc.identifier.citationEuropean urology, 2018, 73 (4), pp. 521 - 523
dc.identifier.issn0302-2838
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1021
dc.identifier.eissn1873-7560
dc.identifier.doi10.1016/j.eururo.2017.12.021
dc.description.abstractIn men with prostate-specific antigen failure after radical radiotherapy, androgen deprivation therapy should be delayed until the site of recurrence is known to allow consideration of curative treatment options, to delay androgen deprivation therapy-related morbidity, and to enable earlier access to abiraterone and docetaxel.
dc.formatPrint-Electronic
dc.format.extent521 - 523
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectNeoplasm Metastasis
dc.subjectNeoplasm Recurrence, Local
dc.subjectAndrogen Antagonists
dc.subjectProstate-Specific Antigen
dc.subjectRadiotherapy
dc.subjectProstatectomy
dc.subjectRisk Assessment
dc.subjectSurvival Analysis
dc.subjectQuality of Life
dc.subjectMale
dc.subjectTime-to-Treatment
dc.subjectClinical Decision-Making
dc.titleManagement of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation.
dc.typeJournal Article
dcterms.dateAccepted2017-12-18
rioxxterms.versionofrecord10.1016/j.eururo.2017.12.021
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2018-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean urology
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/17/18 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/17/18 Starting Cohort
pubs.publication-statusPublished
pubs.volume73
pubs.embargo.termsNot known
icr.researchteamStereotactic and Precision Body Radiotherapyen_US
dc.contributor.icrauthorParker, Chrisen
dc.contributor.icrauthorBrand, Douglasen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record